ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.

Results 1 - 20 of 116 : 1 2 3 4 5 6 Next »

Recs

0
Member Avatar FTownBryan (< 20) Submitted: 4/12/2014 12:53:56 PM : Outperform Start Price: $49.81 ISIS Score: -35.18

good value on the pullback. time to load up.

Recs

0
Member Avatar TMFInnovator (34.92) Submitted: 4/10/2014 2:56:19 PM : Outperform Start Price: $35.30 ISIS Score: -5.11

Coupling this with my recent CAPS pick of ALNY for RNA interference and antisense/gene silencing.

The treatment of genetic diseases is not only a huge market, but one that would truly improve the world. With multiple products in clinical trials and a strong partnering program, I think ISIS is in a great position to benefit. Outperform.

Recs

0
Member Avatar simplemts (< 20) Submitted: 4/3/2014 2:15:00 PM : Underperform Start Price: $39.19 ISIS Score: +12.08

short-term.

Recs

0
Member Avatar NHWeston102 (81.52) Submitted: 3/12/2014 11:30:25 AM : Outperform Start Price: $50.41 ISIS Score: -32.13

Poised to enter the biotech majors, ISIS has pipeline, partnerships, and profits.

Recs

0
Member Avatar 1russianguy (61.77) Submitted: 2/28/2014 12:45:38 PM : Outperform Start Price: $53.76 ISIS Score: -36.42

BG long from around $23 (June 13').

Recs

1
Member Avatar Wildabeast04 (< 20) Submitted: 1/6/2014 2:53:41 PM : Outperform Start Price: $38.79 ISIS Score: -14.33

Huge pipeline of drugs with great space for growth.

Recs

0
Member Avatar MaliLuke (47.46) Submitted: 12/22/2013 5:27:47 AM : Outperform Start Price: $41.25 ISIS Score: -19.73

A transformational opportunity in biotech with 20 products in clinical trials despite flat sales since 2010' means the one substantial blockbuster could be around the corner and provide revenues for its partnerships, which lower the total risks and cash burn-rate since 2007

Recs

1
Member Avatar CatFoodMoney (70.64) Submitted: 12/18/2013 7:38:26 PM : Outperform Start Price: $38.89 ISIS Score: -15.42

I like biotechs.

Recs

0
Member Avatar BJVR (< 20) Submitted: 12/16/2013 7:29:39 PM : Outperform Start Price: $37.84 ISIS Score: -14.04

Because it is a Pharmaceutical company and Medicine is hot now. With ObambaCare coming, people will take more medicine that have surgery.
Bill Jackson
BJVR

Recs

2
Member Avatar goodrisk007 (< 20) Submitted: 9/14/2013 5:28:59 AM : Outperform Start Price: $31.78 ISIS Score: -1.97

one of the best long term biotech investment with more than 30 drug in the pipeline. Have 2 FDA approved drug validating the antisense technology platform. Now with big-pharma backing for the long term and ample cash on hand. A tenbagger in 5 years.

Recs

0
Member Avatar DrLinks (52.23) Submitted: 7/20/2013 4:28:45 PM : Outperform Start Price: $31.79 ISIS Score: -3.04

Phenomenal Biotech with amazing mRNA potential!

Recs

2
Member Avatar arthurs1 (< 20) Submitted: 5/29/2013 3:36:51 PM : Outperform Start Price: $21.91 ISIS Score: +42.62

28 drugs in the pipeline, adding 3 to 5 a year, over 1,500 ASO patents, they are without any doubt the hands down leader in antisense with a dozen or more big pharmas paying them to partner. I said the same thing when it was $8 late last year. They have stated they will report on the Phase II and Phase III progress of 8 or 9 drugs this year, that means in the next 7 months. They have been in biz around 25 years, the difference now is that their drugs are much, much more powerful now.

Recs

2
Member Avatar zzlangerhans (99.73) Submitted: 5/26/2013 2:09:44 AM : Outperform Start Price: $21.34 ISIS Score: +49.04

I was one of those who lost faith in Isis, seeing weak prospects for cholesterol-lowering drug Kynamro vs Aegerion's Juxtapid. However, the stock has now roared back with a new luct\rative partnership with Roche to develop antisense drugs for Huntington's, and the company continues to make progress in their collaborations with Biogen Idec and AstraZeneca as well as in their proprietary antisense programs. There's definitely a strong speculative component to the two billion plus valuation here, but Portefeuille recommended a 300 share buy at 20.14 three weeks ago and this green thumb will support the zzporte position.

Recs

0
Member Avatar Pops61 (62.20) Submitted: 4/11/2013 8:52:27 PM : Outperform Start Price: $19.09 ISIS Score: +60.69

Impressive pipeline of drugs with several partners. Five drugs progressing through Phase 3 trials and NDA by late 2013 and early 2014.

Recs

2
Member Avatar tecno1 (86.72) Submitted: 1/12/2013 2:24:38 PM : Outperform Start Price: $10.07 ISIS Score: +171.02

ISIS has developed in the shades of Kynamro largely unnoticed one of the most diversified and matured drug pipelines with 28 different drugs.
In addition to Kynamro they have five drugs that can reach the marketplace in the next five years and nine drugs with important Phase III or Phase II data points in 2013. They´ll move three programs into Phase III and at least four programs into Phase II in 2013 or early 2014.

In the J.P. Morgan Healthcare Conference presentation CEO Stan Crooke stated that "the level of interest in our technology and our pipeline is at an all-time high". That´s great! Especially because ISIS plan to partner three to four mature programs ( APOC3, Factor XI, CRP and EIF4) in 2013. CEO Stan Crooke believe they can "be licensing opportunities that exceed what we got for Kynamro".

I think now is the time to focus on the whole pipeline! Kynamro is only a minor part of it!

Recs

1
Member Avatar jeffskopp (< 20) Submitted: 10/18/2012 6:34:28 PM : Outperform Start Price: $9.20 ISIS Score: +241.37

26 drugs in pipeline , all with major players

Recs

2
Member Avatar toaoyoda (< 20) Submitted: 2/10/2012 3:12:53 PM : Outperform Start Price: $8.32 ISIS Score: +269.66

This biotech has been "promising" for two decades but its platform seems finally at a critical mass with several drugs poised ( in collaboration with larger, pharma companies ) to enter the market, especially in areas not well-served by other drugs. Intrinsically, the platform should entail fewer side effects than more traditional drugs.

Recs

0
Member Avatar RXDOC73 (99.31) Submitted: 11/22/2011 8:17:23 AM : Outperform Start Price: $6.59 ISIS Score: +359.98

Buyout Potential!

Recs

0
Member Avatar mukwonago53149 (< 20) Submitted: 3/12/2011 12:26:14 AM : Outperform Start Price: $8.91 ISIS Score: +238.32

http://www.caseyresearch.com/crpmkt/Biotech2.php

Recs

0
Member Avatar Willy1g (35.12) Submitted: 12/27/2010 12:10:54 PM : Outperform Start Price: $10.46 ISIS Score: +176.55

A panel of top research/practicing cardiologists explained that the elevation of liver enzymes is common in patients with cardiovascular diseases. They expressed that reducing extremely high cholesterol levels in their patients far-outweighs the often temporary elevation of liver enzymes.

Results 1 - 20 of 116 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement